Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 401 - 450 out of 46,195

Document Document Title
WO/2014/059558
The present invention provides a composition comprising nalbuphine prodrug-Sebacoyl dinalbuphine ester and pharmaceutical biodegradable polymer PLGA. The composition is prepared as a controlled release formulation, which can be implanted...  
WO/2014/059702
Disclosed are benfotiamine polymorphs, preparation method and use thereof. The crystal forms of benfotiamine are A crystal form benfotiamine, B crystal form benfotiamine, C crystal form benfotiamine, D crystal form benfotiamine or E crys...  
WO/2014/061735
 Provided is an improved β-subunit of human β-hexosaminidase, having activity derived from a α-subunit of wild-type human β-hexosaminidase, and having resistance to protease. A protein comprising, in the amino acid sequence for a...  
WO/2014/060113
The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or ...  
WO/2014/060432
New pyrrolotriazinone derivatives having the chemical structure of formula (I), are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositi...  
WO/2014/063087
A synergistic therapeutic effect is obtained in CNS cancer patients treated concomitantly with a first antineoplastic agent and a second antineoplastic agent, wherein one or both antineoplastic agents are administered by convection enhan...  
WO/2014/059383
The present invention provides compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting kinase (e.g., GSK3 (e.g., GSK3a or GS...  
WO/2014/058736
The present disclosure is generally directed to neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the tre...  
WO/2014/057484
An isolated peptide comprising a Huntingtin (Htt) amino acid sequence being no longer than 15 amino acids, wherein said Htt amino acid sequence comprises the sequence X X 2 X 3 X 4 X, wherein X is a hydrophobic amino acid or threonine, X...  
WO/2014/057772
The present invention provides a novel method for treating Alzheimer's disease. A compound expressed by general formula (I) or a salt thereof.  
WO/2014/058742
This invention discloses a treatment for a patient receiving medication to treat an attention deficit disorder such as ADHD wherein the treatment results in a loss of appetite and impairment of the patient's attentiveness. The treatment ...  
WO/2014/059295
Disclosed are methods and compositions for the treatment or prevention of vascular cognitive impairment. The disclosed methods and compositions include rapamycin, a rapamycin analog, or another such inhibitor of the target of rapamycin (...  
WO/2014/059185
The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, R1, R2, R3, R7 and n of Formula I, inde...  
WO/2014/059115
Provided herein are methods, assays and compositions relating to the treatment of neurological diseases and disorders, particularly by modulating expression and/or activity of Bif-1.  
WO/2014/057179
The invention concerns a gaseous composition containing gaseous xenon for use by inhalation in order to prevent or treat at least one neurological consequence secondary to a septic shock in a patient.  
WO/2014/059306
The present invention relates to pyrimidine hydroxy amide compounds, and the use of such compounds in the inhibition of HDAC6 and in the treatment of depression and/or anxiety.  
WO/2014/057995
The objective of the present invention is to provide an extract from inflamed rabbit skin inoculated with vaccinia virus and formulations, etc. including the extract which have greater uniformity in quality. By using the amount of N-acet...  
WO/2014/058071
The present invention provides a compound that: has a lysine-specific demethylase-1-inhibiting effect; and provides utility as a drug for preventing or treating schizophrenia, Alzheimer's disease, Parkinson's disease, and Huntington chor...  
WO/2014/057266
The present invention relates to novel compounds of Formula I capable of inhibiting tissue transglutaminase, and uses of the same in medicine. In particular, the invention provides compounds for use in the treatment of prevention of dise...  
WO/2014/058875
Methods and compositions for enhancing one or more of: myelination, re-myelination, oligodendrocyte numbers, or neuroaxonal protection, while ameliorating an inflammatory condition in a human subject are disclosed. In certain embodiments...  
WO/2014/059346
Disclosed embodiments are related to pharmaceutical compositions and methods for preventing or treating conditions involving dopamine, such as Parkinson's disease, comprising administering to a mammal in need thereof, an effective amount...  
WO/2014/058160
According to the present invention, a composition comprising myricetin or a pharmaceutically acceptable salt thereof as an active ingredient enhances exercise performance and physical strength. Also, the composition has an anti-aging fun...  
WO/2014/057178
The invention concerns a gaseous composition containing gaseous argon for use by inhalation in order to prevent or treat at least one neurological consequence secondary to a septic shock in a patient.  
WO/2014/057727
The purpose is to provide a method for manufacture a fraction containing nobiletin and tangeretin in high concentration and having excellent safety, economic efficiency, and commercialization. The above-stated purpose is achieved by a me...  
WO/2014/059031  
WO/2014/059220
The invention provides, inter alia, immunoinhibitory glycosphingolipids and immunoinhibitory alpha-galactosylceramides and compositions and preparations thereof, and methods of use thereof including in the treatment of conditions charact...  
WO/2014/056620
The invention relates to certain compounds for the use in the treatment and/or prophylaxis of diseases and/or disorders that are, at least partially, mediated by TSPO activity.  
WO/2014/057997
The present invention provides: a method for producing a pluripotent spheroid cell, said method comprising introducing a reprogramming peptide containing a nuclear localization signal into a differentiated cell; a preparation for inducin...  
WO/2014/056779
The invention relates to a drug for the prophylaxis and/or treatment of a neurodegenerative disease.  
WO/2014/057180
The invention concerns a gaseous composition containing a mixture of gaseous xenon and argon for use by inhalation in order to prevent or treat at least one neurological consequence secondary to a septic shock in a patient.  
WO/2014/057484
An isolated peptide comprising a Huntingtin (Htt) amino acid sequence being no longer than 15 amino acids, wherein said Htt amino acid sequence comprises the sequence X1X2X3X4X5, wherein X1 is a hydrophobic amino acid or threonine, X2 is...  
WO/2014/059363
Oral solution formulations of aripiprazole, methods of manufacture of these formulations, methods of administration, and kits containing same.  
WO/2014/058000
The purpose of the present invention is to provide a 5-HT2B receptor antagonist which does not induce problematic adverse side effects or the like and can be used safely. Provided are a serotonin 2B receptor antagonist and a prophylactic...  
WO/2014/058875
Methods and compositions for enhancing one or more of: myelination, re- myelination, oligodendrocyte numbers, or neuroaxonal protection, while ameliorating an inflammatory condition in a human subject are disclosed. In certain embodiment...  
WO/2014/056710
The present invention relates to ethynyl derivatives of formula (I) wherein • R is phenyl, 3-fluorophenyl, 4-fluorophenyl or 2,5-di-fluorophenyl; • or to a pharmaceutically acceptable acid addition salt, in enantiomerically pure form...  
WO/2014/056816
The present invention relates to a combination of an Aβ antibody and a BACE1 inhibitor.  
WO/2014/057435
The present invention relates to [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]- methanone derivatives of formula (I) wherein R, and the rings A1 A2 and A3 are as described in the description, to pharmaceutically ac...  
WO/2014/059029
Disclosed herein are novel compositions and methods for the treatment of age- related diseases, mitochondrial diseases, the improvement of stress resistance, the improvement of resistance to hypoxia and the extension of life span. Also d...  
WO/2014/053418
The present invention relates to a method for obtaining mesenchymal stem cells (MSCs) from mammalian tissue or body fluid, comprising isolating said MSCs from tissue or body fluid and expanding said isolated MSCs in multiple cultivation ...  
WO/2014/055588
The present invention relates to methods of treatment using [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4 -yl}-phenoxy)-propyl]-diethyl amine ("COMPOUND I") or a pharmaceutically acceptable salt thereof. In various embodim...  
WO/2014/054635
Provided is a therapeutic agent for diseases associated with a cholinergic property of the central nervous system (CNS) and/or the peripheral nervous system (PNS), diseases associated with the contraction of smooth muscle, incretion dise...  
WO/2014/055541
The number of acne lesions in a human subject is reduced by administering to the subject a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively...  
WO/2014/055977
The plasma concentration of at least one branched chain amino acid in a mammal in need of such reduction is reduced by administering an agent that increases the plasma concentration of large neutral amino acids. The invention also includ...  
WO/2014/055932
The present invention is an ingestable blended formulation which will cause a series of distinct biochemical changes in-vivo; initiate desirable psychological consequences in that person; and induce an observable increase in cognitive fu...  
WO/2014/055055
A pharmaceutical composition for parenteral administration containing the active ingredient 1-adamantylethyloxy-3-morpholino-2-propanol, or pharmaceutically acceptable salts thereof, in a concentration range of from 3 to 100 mg/ml for th...  
WO/2014/055949
The invention generally features isolated platelets, compositions, methods, and kits useful for targeted delivery of one or more therapeutic agents to a site of injury, inflammation, disease, or disorder. Also featured are methods and ki...  
WO/2014/055047
The present invention is related to pharmaceutical compositions comprising idebenone and donepezil for use in symptomatic treatment of cerebral arteriosclerosis, symptoms following stroke and cerebral hemorrhage, age-associated cognitive...  
WO/2014/054965
The invention relates to the field of pharmacology and practical medicine, and specifically to the combined use of medicinal preparations, with neuro-tropic action, alleviating the manifestation of mental, behavioural and cognitive di...  
WO/2014/053418
The present invention relates to a method for obtaining mesenchymal stem cells (MSCs) from mammalian tissue or body fluid, comprising isolating said MSCs from tissue or body fluid and expanding said isolated MSCs in multiple cultivation ...  
WO/2014/054634
Provided is a therapeutic agent for diseases associated with a cholinergic property of the central nervous system (CNS) and/or the peripheral nervous system (PNS), diseases associated with the contraction of smooth muscle, incretion dise...  

Matches 401 - 450 out of 46,195